Contents - Middle East Journal of Family Medicine

REVIEW ARTICLESREFERENCES1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative studygroup:the effect of angiotensin-converting enzyme inhibition on diabeticnephropathy Engl J Med 1993,329:1456-1462.2. The ACE inhibitors in diabetic nephropathy trialist group: Should allpatients with type 1 diabetes mellitus and microalbuminuria receiveangiotensin - converting enzyme inhibitors? Ameta-Analysis of individualpatient data.Ann intern med 2001,134:370 - 379.3. Bakris GL,Weir MR: ACE inhibitors-associated elevations in serumCreatinine:is this a cause for concern?. Arch intern med 2000,160:685 -693.4. Israili ZH,Hall WD:Cough and angioneurotic edema associated withangiotensin-converting enzyme inhibitor therapy:A review of the literatureand pathophisiology.Ann Intern Med 117:324-242,1992.5. Israili ZH,Hall WD:Cough and angioneurotic edema associated withangiotensin-converting enzyme inhibitor therapy:A review of the literatureand pathophisiology.Ann Intern Med 117:324-242,1992.6. Skeggs, L.T., Kahn, J.R., and Shumway, N.P.1956.The preparation andfunction of the hypertension converting enzyme..J Exp Med 103:295-299.7. Ferreira,S.H.1965.A bradykinin-potentiating factor (BPF) present in thevenom of Bothrops jararaca.Brit J Pharmacol 24:163-169.8. Bakhle,Y.S.1968.conversion of angiotensin I to angiotensin II by cell freeextracts of dog lung. Nature 220:919-921.9. Ferreira,S.H. Bartel,D.C. and Greene,L.J.1970.Isolation of bradykininpotentiatingpeptides from Bothrops Jararaca Venom.Biochemistry9:2583-2593.10. Ondetti,M.A, Williams,N.J, Sabo,E.F., Pluscec,J. Weaver,E.R., andKocy,o.1971.Angiotensin-converting enzyme inhibitors from the venomof Bothrops Jararaca.Isolation,elucidation of structure,and synthesis.Biochemistry 10:4033 - 4039.11. Reichert, J. M., Milne, C.-P. (2002) Public and private sector contributionsto the discovery and development of ‘impact’ drugs Tufts Center for theStudy of Drug Development Boston MA.12. Page IH&Bumus FM 1974 Angiotensin.New York: Springer Verlag.13. Fitzimons JT 1998 Angiotensin, thirst and sodium appetite. PhysiologicalReviews 78 583-686.14. Menard J,Clauser E,Bouhnik J & Corvol P 1993 Angiotensinogen:biochemical aspects. In the Renin Angiotensin System,pp 8.1-8.10.Eds JISRobertson & MS Nichollas.London:Gower Medical Publishing.15. William F.Ganong. Review of medical physiology 19th edition.Appleton& Lange 1999.16. Caldwell PRB,Seegal BC,Hsu KC,Das M & Soffer RL 1976 Angiotensinconvertingenzyme:vascular endothelial localization. Science 191 1050-1051.17. De Gasparo M , Catt KJ, Inagami T, Wright JW & Unger TH 2000angiotensin II receptors. Pharmacological Reviews 52 412-472.18. Chung O, Kuhl H, Stoll M, Unger T: physiology and pharmacologicalimplications of AT1 versus AT2 receptors. Kidney Int 54(Suppl 67):S95-S99,1998.19. Siragy HM,Carey RM:the subtype 2 (AT2) angiotensin receptor regulatesrenal prostaglandin F2 alpha formation in conscious rats.Am J Physiol273:R1103-R1107,1997.20. Campbell DJ, Habener JF. Cellular localization of AGT gene expression inbrown adipose tissue and mesentry: quantification of messenger ribonucleicacid abundance using hybridization in site.Endocrinology.1987;121:1616-1626.21. Stern MP 1995 Diabetes and cardiovascular disease: the common soilhypothesis.diabetes 44 369-374.22. Efficacy of atenolol and captopril in reducing risk of macrovascularand microvascular complications in type 2 diabetes: UKPDS 39.UKprospective diabetes study group.BMJ.1998;317(7160):713-720.23. Effects of Ramipril on cardiovascular and microvascular outcomes inpeople with diabetes mellitus: result of HOPE study and MICRO-HOPEsubstudy. Heart Outcome Prevention Evaluation study investigators.Lancet 2003;355(9200);253-259.24. Villarosa IP,Bakris GL.The appropriate blood pressure control in diabetes(ABCD) trial Human Hypertension 1998 Sep;12(9):653-525. Scheen AJ. Clinical study of the month. The CAPPP Study:the CaptoprilPrevention Project.Rev Med Liege 1999;54(3):197-926. Tatti P,Pahor M,Byington RP,Di Mauro P,Guarisco R, Strollo F. outcomeresults of the Fosinopril versus Amlodipine Cardiovascular eventsRandomized Trial (FACET) in patients with hypertension and NIDDM.Diabetes Care.1998;21 (4):597-603.MEJFM - Volume 5 Issue 1 - January 2007 35